ライフサイエンスコーパス: glycopyrrolate

1 following cardiac parasympathetic blockade (glycopyrrolate).

2 in salivary response to an anti-sialogogue (glycopyrrolate).

3 ts with and without cholinergic blockade via glycopyrrolate.

4 lder--60-77 yrs) received 4.0 microg/kg i.v. glycopyrrolate.

5 g min-1) were assessed after vagal blockade (glycopyrrolate, 1.2 mg).

6 0.16 +/- 0.01 mg kg(-1); mean +/- S.E.M.) or glycopyrrolate (12.6 +/- 1.6 microg kg-1).

7 .003 mg kg(-1)) or parasympathetic blockade (glycopyrrolate, 13.6 +/- 1.5 microg kg(-1)).

8 daily), indacaterol (27.5 mug twice daily), glycopyrrolate (15.6 mug twice daily), or placebo, all d

9 o receive either indacaterol (27.5 mug) plus glycopyrrolate (15.6 mug) or placebo twice daily for 12

10 nts were randomized (1:1:1:1) to indacaterol/glycopyrrolate (27.5/15.6 mug twice daily), indacaterol

11 ith subjects who received the active placebo glycopyrrolate (4 microg/kg) and subjects who were not i

12 P < 0.05, n = 3) following administration of glycopyrrolate (-8.1 +/- 4.5 ms) compared to PS alone (-

13 e efficacy and safety of QVA149 (indacaterol/glycopyrrolate), a fixed-dose combination of a long-acti

14 We used glycopyrrolate, a nonspecific muscarinic (parasympatheti

15 ses in isolated guinea pig vagal tissue, but glycopyrrolate and atropine did not.

16 control (no drug), parasympathetic blockade (glycopyrrolate) and beta-adrenergic blockade (metoprolol

17 edication use were observed with indacaterol/glycopyrrolate compared with placebo (P < 0.001).

18 ol) and a long-acting muscarinic antagonist (glycopyrrolate), compared with its monocomponents and pl

19 e (metoprolol) and parasympathetic blockade (glycopyrrolate) conditions.

20 s during which they received neostigmine and glycopyrrolate for NMB reversal.

21 to harm 97) among those receiving budesonide-glycopyrrolate-formoterol compared to fluticasone-umecli

22 Patients who received budesonide-glycopyrrolate-formoterol had a 9% higher incidence of f

23 lidinium-vilanterol compared with budesonide-glycopyrrolate-formoterol in people with COPD.

24 New initiators of budesonide-glycopyrrolate-formoterol or fluticasone-umeclidinium-vi

25 Budesonide-glycopyrrolate-formoterol was not associated with improv

26 NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates o

27 se mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/f

28 inistration of either propranolol (PROP), or glycopyrrolate (GLYC), or PROP and GLYC in combination (

29 blockade (NMB) reversal with neostigmine and glycopyrrolate has been reported to cause cardiac arrest

30 8.0 mg propranolol i.v. and (3) after 0.8 mg glycopyrrolate i.v.

31 would support the safety of neostigmine and glycopyrrolate in cardiac transplantation patients.

32 Whereas pilocarpine and glycopyrrolate increased and decreased sweating, respect

33 Metoprolol decreased and glycopyrrolate increased HR and cardiac output both at r

34 bacine) and slowly dissociating (tiotropium, glycopyrrolate) ligands.

35 alue of the reward, we tested the effects of glycopyrrolate on a food preference task.

36 . = 1.28-2.26) outperformed placebo, but not glycopyrrolate or ipratropium.

37 ases in vagal tone were induced using either glycopyrrolate or mild rhythmic exercise.

38 trol of HR was significantly attenuated with glycopyrrolate (P < 0.05).

39 Glycopyrrolate reduced the maximal gain (G(max)) ofthe C

40 Indacaterol/glycopyrrolate twice daily can be an alternative treatme

41 o demonstrate the superiority of indacaterol/glycopyrrolate versus its monocomponents for standardize

42 daily rescue medication use with indacaterol/glycopyrrolate versus placebo.

43 Indacaterol/glycopyrrolate was statistically superior in terms of FE

44 Focusing on one of these hits, glycopyrrolate, we confirm the role for muscarinic choli

45 R) during isoproterenol, dexmedetomidine and glycopyrrolate were given.